As 2015 winds down, this would be an opportune time to look at learnings from the last year within the healthcare industry, as well as the future insights from healthcare stakeholders. Curant Health COO, Marc O’Connor, gives his insights on developments providers, manufacturers and payers have seen this year and where future developments will take them […]
December 9, 2015 - Curant COO, Marc O'Connor, in Managed Healthcare Executive - Unwinding a healthcare system built on decades of fee-for-service delivery will not come easily. Nevertheless, 2015 saw several major healthcare changes that will enable the industry to begin to use value from innovation in technology, pharmaceuticals and clinical care as its defining […]
At the end of 2010, the American South accounted for 45% of the estimated 33,015 new AIDS diagnoses in the 50 states and the District of Columbia, followed by the Northeast (24%), the West (19%), and the Midwest (13%).1 On the front lines of this epidemic, The University of Alabama-Birmingham 1917 Clinic serves more than […]
Recently, there has been buzz on the top therapeutic areas to watch for in the healthcare world in 2016. In a recent edition of Managed Healthcare Executive, Curant COO Marc O’Connor gives his perspective on a few upcoming hot healthcare hot topics for next year. Prominent categories of healthcare quickly becoming the center of attention […]
November 30, 2015 - Curant Health COO, Marc O'Connor, in Managed Healthcare Executive - This year, many new medications and treatments emerged to improve the management and prognoses of patients suffering from serious illnesses. But while these developments represent promise, they also raise complex decisions related to cost and quality. In 2016, as these developments […]
Recently, Curant COO Marc O’Connor spoke with Renay San Miguel from Georgia Public Broadcasting on the Curant’s prescription for growth. In addition to its superior patient care model, with an established 98% retention rate, Curant’s financial success has caught the attention of industry leaders. Since its inception in 2000, Curant has been recognized by industry […]
July 30, 2015 - Curant Health President and CEO, Patrick Dunham, in MedCity News - In my role as CEO of one of the nation’s largest independent 340B specialty pharmacies, I found the past six months leading up to the 340B Coalition Summer 2015 Conference were much quieter than in the past. Is the healthcare […]
Presenting with a CD4 count of only 21, doctors gave Robert W. mere months to live. Weighing only 98 pounds, his HIV had progressed to Stage 3 AIDS, and he was on his deathbed. Robert had been prescribed seven different HIV medications and had a long history of struggling with his HIV treatment compliance due […]
The writing has been on the wall from some time. The push for value-based care has had a domino effect on biopharmaceutical manufacturers. The new industry trend will be for them to go “at-risk” in negotiations with payers and PBMs for new high-cost specialty therapies. Factors that increase the need for biopharma manufacturers to go […]
November 17, 2015 - Curant COO, Marc O'Connor, in Specialty Pharmacy Times - During a strategy session in June, my colleagues at Curant Health and I identified the need for biopharmaceutical manufacturers to go “at risk” in negotiations with payers and PBMs for new high cost specialty therapies as a near-term industry trend. “At risk” […]
